CD274 and cancer: As Chen and colleagues have shown, Siglec15 overexpression has been documented in numerous human cancers and its expression is mutually exclusive of PD-L1, suggesting that it may be a potential therapeutic target for patients who are refractive to anti-PD-1/PD-L1 checkpoint blockade therapy42.